Results of the Cologne Corona surveillance (CoCoS) study – a prospective population-based cohort study: incidence data and potential underestimation of new SARS-CoV-2 adult infections by health authorities

• Published in: BMC public health Vol. 22; no. 1; pp. 1 - 1379
• Main Authors: Oberste, Max, Pusch, Lynn-Marie, Roth, Rebecca, Shah-Hosseini, Kija, Schmitz, Jana, Heger, Eva, Dewald, Felix, Müller, Claudia, von Goltzheim, Luise Stach, Lehmann, Clara, Buess, Michael, Wolff, Anna, Fätkenheuer, Gerd, Wiesmüller, Gerhard, Klein, Florian, Rosenberger, Kerstin Daniela, Neuhann, Florian, Hellmich, Martin
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 19.07.2022; BioMed Central; BMC
• Subjects: Clinical trials; Cohort analysis; Coronavirus; Coronaviruses; COVID-19; COVID-19 vaccines; Epidemiology; Estimates; Immunization; Incidence; Infection control; Infections; Laboratories; Methods; Pandemic; Pandemics; Population; Population studies; Population-based studies; Public health; Questionnaires; Registration; Saliva; Severe acute respiratory syndrome coronavirus 2; Sociodemographics; Statistical analysis; Surveillance; Test methods; Underestimation; Vaccines; Germany
• ISSN: 1471-2458; 1471-2458
• DOI: 10.1186/s12889-022-13745-1

Abstract Background Current incidence estimates of SARS-CoV-2 in Germany rely to a large extent on case notifications. However, the large number of mild or asymptomatic infections is likely to result in underestimation. Population-based studies can provide valid estimates of the SARS-CoV-2 incidence and thus support health authorities to monitor the epidemiological situation and to initiate, maintain, strengthen or relax effective countermeasures. Methods This study was conducted in Cologne, Germany. Six-thousand randomly drawn Cologne residents, 18 years of age or older, were contacted by mail in March 2021. Study envelopes contained a kit for self-administered saliva sample and access details to a questionnaire on sociodemographic characteristics, previous positive SARS-CoV-2 RT-qPCR and completed COVID-19 vaccinations. Participants were again invited for a second round in June 2021, while those who declined participation were replaced by additional randomly drawn Cologne residents in order to reach a total of 6000 potential participants again. The saliva samples were sent to the laboratory by mail and tested for SARS-CoV-2 using RT-qPCR. The incidence estimates were adjusted for sensitivity and specificity of the test procedure and compared with the official numbers of new SARS-CoV-2 cases in the adult Cologne population. Results The first surveillance round in March 2021 (response rate: 34.08%, N  = 2045) showed a SARS-CoV-2 seven-day incidence of 85 cases per 100,000 adult Cologne residents (95% CI: 9 to 319). In the same period, the officially registered cases were 125 per 100,000. The second surveillance round in June 2021 (response rate: 36.53%, N  = 2192) showed a seven-day incidence of 27 per 100,000 adult Cologne residents (95% CI: 1 to 142), while the official figures for newly registered SARS-CoV-2 cases in the same period were 15 per 100,000. Conclusions The incidence estimates do not indicate relevant underestimation of new SARS-CoV-2 infections based on case notification. Regular use of the surveillance method developed here may nevertheless complement the efforts of the health authorities to assess the epidemiological situation. Trial registration DRKS.de, German Clinical Trials Register (DRKS), Identifier: DRKS00024046 , Registered on 25 February 2021.